This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Douglas E. Mattox, MD; Daniel D. Von Hoff, MD

Arch Otolaryngol. 1980;106(11):672-674.

Abstract
• The soft-agar stem-cell assay was applied to head and neck cancer. We have successfully grown 23 (64%) of 36 head and neck tumors from both primary lesions and metastases. More poorly differentiated tumors had positive cultures more frequently than well-differentiated tumors. The plating efficiency (colonies per cells in the inoculum) averaged 0.006% (range, 0.001% to 0.08%). The system allows testing and sensitivity of individual tumors to cancericidal drugs, and our initial trials using methotrexate, bleomycin sulfate, and cisplatin (cisplatinum) show a high degree of variability between individual tumors.

(Arch Otolaryngol 106:672-674, 1980)

Author Affiliations
From the Divisions of Otolaryngology (Dr Mattox) and Oncology (Dr Von Hoff), University of Texas Health Science Center at San Antonio.

Footnotes
Accepted for publication July 11, 1980.

Read before the American Society for Head and Neck Surgery, Palm Beach, Fla, April 17, 1980.

Reprints not available.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cytotoxic Drug Testing in Head and Neck Cancer by Multiparametric Flow Cytometry
Wustrow et al.
Arch Otolaryngol Head Neck Surg 1986;112:1078-1084.
ABSTRACT  

Human Tumor Cloning Assay in Advanced Head and Neck Cancer: Prospective Correlative Trial
Mattox et al.
Arch Otolaryngol Head Neck Surg 1983;109:724-726.
ABSTRACT